Accelero Biostructures and SARomics Biostructures Announce Strategic Collaboration to Expand Protein X-Ray Crystallography and Structure-Based Drug Discovery Services.
SAN FRANCISCO and LUND, Sweden, April 1, 2026 /PRNewswire-PRWeb/ -- Accelero Biostructures Inc. and SARomics Biostructures AB, established providers of structural biology services, including protein X-ray crystallography, and structure- and fragment-based drug discovery services for more than 10 years and 20 years, respectively, are proud to announce a new strategic collaboration.
This partnership is designed to streamline workflows, reduce redundancy, and expand service capabilities, enabling both companies to extend their combined expertise and experience to a broader range of biopharma and biotech companies worldwide. Together, the companies will provide seamless and comprehensive gene-to-structure solutions in crystallography and structural biology. With operations in the San Francisco Bay Area and Sweden, the collaboration strengthens global reach, improves operational efficiency, and allows both companies to maintain a clear focus on their respective strengths.
The gene-to-structure workflow in protein X-ray crystallography and structure-based drug discovery involves three key stages: crystallization-grade protein production, protein crystallization, and structure determination by X-ray crystallography. These stages have varying levels of complexity depending on the scope of the project, including novel protein structures, protein-protein complexes, antibody-antigen complexes, iterative co-crystal structure determination of protein-ligand complexes, or fragment screening by crystallography.
Under the collaboration, Accelero Biostructures will focus on its key strengths in high-throughput iterative co-crystal structure determination of protein-ligand complexes in structure-based drug discovery projects, including synchrotron X-ray screening, data collection, processing, structure determination and analysis, while leveraging SARomics Biostructures' expertise in crystallization-grade protein production and crystallization of challenging targets. Accelero will continue to support crystallographic fragment screening and AI drug discovery efforts and maintain a strong intellectual property position in the United States. SARomics Biostructures will continue to focus on its core expertise in antibody-antigen complexes, novel protein structures, protein-protein complexes, fragment screening by crystallography, WAC™ and NMR, while also performing co-crystallography where appropriate using its extensive portfolio of FastLane™ off-the-shelf protein structures. SARomics hereby also adds cryo-EM to its wide range of service offerings.
"Together, Accelero Biostructures and SARomics Biostructures are able to dramatically accelerate projects for our customers, combining decades of scientific expertise with a cutting-edge approach to protein X-ray crystallography, structural biology, fragment screening and structure- and fragment-based drug discovery. The Co-founders and CEOs of both Accelero Biostructures and SARomics Biostructures, Drs. Debanu Das and Björn Walse, share many common experiences that bring context and value to committing to shared goals in the years ahead: extensive experience in drug discovery, research management, operating companies, and common point of postdoctoral training at the University of California, Berkeley, making it of joint interest to have footprints spanning California and Sweden", said Debanu Das, Accelero Biostructures Co-founder and CEO.
"By combining the complementary strengths of both companies, we believe we can even further accelerate discovery of novel therapies through structural insight", said Björn Walse, SARomics Biostructures Co-founder and CEO.
About Accelero Biostructures: Accelero Biostructures (www.accelerobio.com) was founded in 2015 to capitalize on over 20 years of structural genomics, structural biology and structure-based drug discovery expertise using high-throughput protein X-ray crystallography with the ABS-Services and ABS-OneStep platforms. ABS-Services provides a unified pipeline of protein X-ray crystallography solutions aimed at the pharmaceutical and biotechnology industries to support structure-based drug discovery and protein engineering. ABS-OneStep is the next-generation platform for hit generation in early drug discovery to develop novel therapeutics using a fragment-based drug discovery (FBDD) approach. Fragment library screening with ABS-OneStep resolves key bottlenecks in conventional FBDD approaches. ABS-OneStep provides an extremely sensitive, efficient, experimental, single-step approach for determining fragment hits and their 3D structures using high-throughput protein X-ray crystallography. Accelero Biostructures is based on about 50 years of combined experience in applications and methods development of their two founders in protein X-ray crystallography and its high-throughput applications in SBDD, FBDD, structural genomics and structural biology. Accelero founders have authored/co-authored about 200 publications on applications and methods development in the field, including four publications with Nobel Laureates David Baker, Michael Levitt, Shinya Yamanaka and Kurt Wüthrich.
About SARomics Biostructures: SARomics Biostructures (www.saromics.com) is independent, co-founder owned, and was founded in 2006 by scientists with extensive experience in structural biology and structure-based drug design. Headquartered in Lund, Sweden, in the center of Medicon Valley, Scandinavia's largest biotech cluster, and with proximity to the world-class MAX IV synchrotron, the company has established itself as a leading provider of integrated structural biology and early-stage drug discovery services. SARomics supports the full drug discovery process, from fragment screening for hit identification to structure-based drug design support throughout lead optimization. Its comprehensive platform includes high-quality protein production, X-ray crystallography, NMR spectroscopy (BioNMR), fragment-based screening using NMR, weak-affinity chromatography (WAC™), and crystallography, as well as computational chemistry and virtual screening. The company offers an extensive FastLane™ library of over 600 off-the-shelf crystallization-grade proteins for rapid structure determination. Since its founding, SARomics has solved thousands of protein structures, deposited hundreds in the Protein Data Bank, and contributed to high-impact scientific publications while serving top pharmaceutical companies and innovative biotech firms worldwide. By combining deep scientific expertise, state-of-the-art technologies, and a strong client-focused approach, SARomics Biostructures delivers reliable, high-quality structural insights that accelerate and de-risk drug discovery programs.
Media Contact
Debanu Das, Accelero Biostructures Inc., 1 6502390149, [email protected], https://www.accelerobio.com/
SOURCE Accelero Biostructures Inc.
Share this article